#161774

OV-2295(R2) cell line

Cat. #161774

OV-2295(R2) cell line

Cat. #: 161774

Organism: Human

Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: OV-2295(R2) cell line
  • Alternate name: OV-2295(R2)
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
  • Donor: Grade 3 – Stage IIIC; Mutations: TP53 Exon 6; Cisplatin/Topotecan &; Paclitaxel/Carboplatin/Doxorubicin
  • Morphology: Aquired resistance to carboplatin. Expresssion of tumor suppressor p53 present. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: semi compact
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Post -chemoteherapy derived epithelial ovarian cancer cell line from recurrent disease. Primary treatment was a combination of cisplatin/topotecan and later treatment included carboplatin, paclitaxel, and doxorubicin
  • Production details: Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement.
  • Additional notes: Patient 2295 was diagnosed with ovarian cancer following imaging, ascites puncture, and partial ommentectomy. Patient was included in a clinical trial and treated with cisplatin/topotecan for the first four months following diagnosis. From months 4-7, patient received carboplatin and paclitaxel and responded well to chemotherapy initially. Three months after the end of chemotherapy however, ascites volume increased and later underwent ovarian cytoreduction. Eleven months after diagnosis, she ...

Handling

  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin

References

  • Tomas et al. 2023. J Ovarian Res. 11
  • 16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11
  • 12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11
  • 12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4
  • 12:856424. PMID: 35600398